SCHEMBL20810058

SCHEMBL20810058

O=C(OCc1cc(-c2ccccc2Cl)no1)c1cc(Cl)cnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 6/20 0.46
▸ CYP2C19 P33261 6/20 0.46
▸ MAPT P10636 5/20 0.46
▸ CYP2D6 P10635 4/20 0.46
▸ CYP3A4 P08684 3/20 0.46
▸ HTT P42858 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ NPC1 O15118 3/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ POLB P06746 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ CHRNB2 P17787 1/20 0.43
▸ CHRNA4 P43681 1/20 0.43
▸ CASP3 P42574 1/20 0.42
▸ SENP8 Q96LD8 1/20 0.42
▸ SENP7 Q9BQF6 1/20 0.42
▸ SENP6 Q9GZR1 1/20 0.42
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20810028 0.89 TDP1 (0.43) CYP1A2CYP2C19MAPTCYP2D6SMN1; SMN2
SCHEMBL20810052 0.89 L3MBTL1 (0.45) CYP1A2CYP2C19MAPTCYP2D6HTT
SCHEMBL20810013 0.88 MAPT (0.54) CYP1A2CYP2C19MAPTSMN1; SMN2NPC1
SCHEMBL20810020 0.88 POLB (0.44) MAPTSMN1; SMN2NPC1RAB9APOLB
SCHEMBL20810044 0.87 CASP3 (0.59) CYP1A2CYP2C19MAPTCYP2D6CYP3A4
SCHEMBL20810023 0.87 MAPT (0.38) CYP1A2CYP2C19MAPTCYP2D6SMN1; SMN2
SCHEMBL20810057 0.84 SMN1; SMN2 (0.52) CYP1A2CYP2C19MAPTCYP2D6CYP3A4
SCHEMBL20810024 0.82 SMN1; SMN2 (0.46) MAPTHTTSMN1; SMN2NPC1RAB9A
SCHEMBL20810025 0.82 RAB9A (0.46) MAPTHTTSMN1; SMN2NPC1RAB9A
SCHEMBL20810018 0.81 L3MBTL1 (0.44) MAPTHTTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR3, NAPRT CYP1A2 1321/4885CYP2C19 1283/4885MAPT 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback